Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series.

Mohler JL, Halabi S, Ryan ST, Al-Daghmin A, Sokoloff MH, Steinberg GD, Sanford BL, Eastham JA, Walther PJ, Morris MJ, Small EJ.

Prostate Cancer Prostatic Dis. 2019 May;22(2):309-316. doi: 10.1038/s41391-018-0106-1. Epub 2018 Nov 1.

2.

Effect of positive end-expiratory pressure on blood loss during retropubic and robot-assisted laparoscopic radical prostatectomy.

Ehieli EI, Howard LE, Monk TG, Ferrandino MN, Polascik TJ, Walther PJ, Freedland SJ.

Int J Urol. 2016 Aug;23(8):674-8. doi: 10.1111/iju.13125. Epub 2016 May 25.

3.

Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL Jr, Baker LH.

JAMA. 2011 Oct 12;306(14):1549-56. doi: 10.1001/jama.2011.1437.

4.

Factors predicting early and late phase decline of sexual health-related quality of life following radical prostatectomy.

Kimura M, BaƱez LL, Schroeck FR, Gerber L, Qi J, Satoh T, Baba S, Robertson CN, Walther PJ, Donatucci CF, Moul JW, Polascik TJ.

J Sex Med. 2011 Oct;8(10):2935-43. doi: 10.1111/j.1743-6109.2011.02387.x. Epub 2011 Jul 19.

PMID:
21771284
5.

Salvage radiation in men after prostate-specific antigen failure and the risk of death.

Cotter SE, Chen MH, Moul JW, Lee WR, Koontz BF, Anscher MS, Robertson CN, Walther PJ, Polascik TJ, D'Amico AV.

Cancer. 2011 Sep 1;117(17):3925-32. doi: 10.1002/cncr.25993. Epub 2011 Mar 22.

6.

Adjuvant versus salvage radiation therapy for prostate cancer and the risk of death.

D'Amico AV, Chen MH, Sun L, Lee WR, Mouraviev V, Robertson CN, Walther PJ, Polascik TJ, Albala DM, Moul JW.

BJU Int. 2010 Dec;106(11):1618-22. doi: 10.1111/j.1464-410X.2010.09447.x.

7.

Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death.

Choueiri TK, Chen MH, D'Amico AV, Sun L, Nguyen PL, Hayes JH, Robertson CN, Walther PJ, Polascik TJ, Albala DM, Moul JW.

Cancer. 2010 Apr 15;116(8):1887-92. doi: 10.1002/cncr.25013.

8.

Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras.

Sun L, Caire AA, Robertson CN, George DJ, Polascik TJ, Maloney KE, Walther PJ, Stackhouse DA, Lack BD, Albala DM, Moul JW.

J Urol. 2009 Nov;182(5):2242-8. doi: 10.1016/j.juro.2009.07.034. Epub 2009 Sep 16.

PMID:
19758616
9.

Predictors of variation in serum IGF1 and IGFBP3 levels in healthy African American and white men.

Hoyo C, Grubber J, Demark-Wahnefried W, Lobaugh B, Jeffreys AS, Grambow SC, Marks JR, Keku TO, Walther PJ, Schildkraut JM.

J Natl Med Assoc. 2009 Jul;101(7):711-6.

10.

Bladder cancer.

Montie JE, Clark PE, Eisenberger MA, El-Galley R, Greenberg RE, Herr HW, Hudes GR, Kuban DA, Kuzel TM, Lange PH, Lele SM, Michalski J, Patterson A, Pohar KS, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Walther PJ, Wilson TG; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2009 Jan;7(1):8-39. No abstract available.

PMID:
19176203
11.

Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery.

Demark-Wahnefried W, Polascik TJ, George SL, Switzer BR, Madden JF, Ruffin MT 4th, Snyder DC, Owzar K, Hars V, Albala DM, Walther PJ, Robertson CN, Moul JW, Dunn BK, Brenner D, Minasian L, Stella P, Vollmer RT.

Cancer Epidemiol Biomarkers Prev. 2008 Dec;17(12):3577-87. doi: 10.1158/1055-9965.EPI-08-0008.

12.

Grade-specific prostate cancer associations of IGF1 (CA)19 repeats and IGFBP3-202A/C in blacks and whites.

Hoyo C, Grubber J, Demark-Wahnefried W, Marks JR, Freedland SJ, Jeffreys AS, Grambow SC, Wenham RM, Walther PJ, Schildkraut JM.

J Natl Med Assoc. 2007 Jul;99(7):718-22.

13.

Bladder cancer. Clinical guidelines in oncology.

Montie JE, Abrahams NA, Bahnson RR, Eisenberger MA, El-Galley R, Herr HW, Hudes GR, Kuzel TM, Lange PH, Patterson A, Pollack A, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Walther PJ, Wilson TG; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2006 Nov;4(10):984-1014. No abstract available.

PMID:
17112448
14.

Supplement use among men with prostate cancer.

Wiygul JB, Evans BR, Peterson BL, Polascik TJ, Walther PJ, Robertson CN, Albala DM, Demark-Wahnefried W.

Urology. 2005 Jul;66(1):161-6.

PMID:
15992901
15.

IGF1 (CA)19 repeat and IGFBP3 -202 A/C genotypes and the risk of prostate cancer in Black and White men.

Schildkraut JM, Demark-Wahnefried W, Wenham RM, Grubber J, Jeffreys AS, Grambow SC, Marks JR, Moorman PG, Hoyo C, Ali S, Walther PJ.

Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):403-8.

16.

Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

Lippman SM, Goodman PJ, Klein EA, Parnes HL, Thompson IM Jr, Kristal AR, Santella RM, Probstfield JL, Moinpour CM, Albanes D, Taylor PR, Minasian LM, Hoque A, Thomas SM, Crowley JJ, Gaziano JM, Stanford JL, Cook ED, Fleshner NE, Lieber MM, Walther PJ, Khuri FR, Karp DD, Schwartz GG, Ford LG, Coltman CA Jr.

J Natl Cancer Inst. 2005 Jan 19;97(2):94-102.

PMID:
15657339
17.

Bladder cancer. Clinical practice guidelines in oncology.

Montie JE, Bahnson RR, Cohen SM, Drucker B, Eisenberger MA, El-Galley R, Herr HW, Hudes GR, Kuzel TM, Lange PH, Patterson A, Pollack A, Richie JP, Seigne J, Shipley WU, Small EJ, Trump DL, Walther PJ, Wilson TG; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2005 Jan;3(1):4-5, 19-34.

PMID:
19813320
18.

Pilot study to explore effects of low-fat, flaxseed-supplemented diet on proliferation of benign prostatic epithelium and prostate-specific antigen.

Demark-Wahnefried W, Robertson CN, Walther PJ, Polascik TJ, Paulson DF, Vollmer RT.

Urology. 2004 May;63(5):900-4.

PMID:
15134976
19.

Glucocorticoids manifest androgenic activity in a cell line derived from a metastatic prostate cancer.

Chang CY, Walther PJ, McDonnell DP.

Cancer Res. 2001 Dec 15;61(24):8712-7.

20.

Pilot study of dietary fat restriction and flaxseed supplementation in men with prostate cancer before surgery: exploring the effects on hormonal levels, prostate-specific antigen, and histopathologic features.

Demark-Wahnefried W, Price DT, Polascik TJ, Robertson CN, Anderson EE, Paulson DF, Walther PJ, Gannon M, Vollmer RT.

Urology. 2001 Jul;58(1):47-52.

PMID:
11445478
21.
22.

Time for a neoadjuvant chemotherapy strategy in prostate cancer?

Walther PJ.

Curr Opin Urol. 2000 May;10(3):225-7. No abstract available.

PMID:
10858901
23.

Early onset baldness and prostate cancer risk.

Denmark-Wahnefried W, Schildkraut JM, Thompson D, Lesko SM, McIntyre L, Schwingl P, Paulson DF, Robertson CN, Anderson EE, Walther PJ.

Cancer Epidemiol Biomarkers Prev. 2000 Mar;9(3):325-8.

24.
25.

Treatment options, selection, and satisfaction among African American and white men with prostate carcinoma in North Carolina.

Demark-Wahnefried W, Schildkraut JM, Iselin CE, Conlisk E, Kavee A, Aldrich TE, Lengerich EJ, Walther PJ, Paulson DF.

Cancer. 1998 Jul 15;83(2):320-30.

PMID:
9669815
26.

The treatment of metastatic renal cell carcinoma patients with recombinant human gamma interferon.

Small EJ, Weiss GR, Malik UK, Walther PJ, Johnson D, Wilding G, Kuzel T, Bajamonde A, Paton V.

Cancer J Sci Am. 1998 May-Jun;4(3):162-7.

PMID:
9612597
27.

Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer.

Carstens RP, Eaton JV, Krigman HR, Walther PJ, Garcia-Blanco MA.

Oncogene. 1997 Dec 18;15(25):3059-65.

28.

A prostate screening perspective.

Walther PJ.

N C Med J. 1996 Nov-Dec;57(6):341. No abstract available.

PMID:
8937155
30.

p53 immunohistochemical and genetic alterations are associated at high incidence with post-irradiated locally persistent prostate carcinoma.

Prendergast NJ, Atkins MR, Schatte EC, Paulson DF, Walther PJ.

J Urol. 1996 May;155(5):1685-92.

PMID:
8627854
31.

"Wildcatting" for breakthroughs in urothelial cancer detection and management--a frustrating business.

Walther PJ.

J Urol. 1995 Oct;154(4):1348-50. No abstract available.

PMID:
7544837
32.

Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma.

Law TM, Motzer RJ, Mazumdar M, Sell KW, Walther PJ, O'Connell M, Khan A, Vlamis V, Vogelzang NJ, Bajorin DF.

Cancer. 1995 Sep 1;76(5):824-32.

PMID:
8625186
33.
34.

Genetic alterations in prostate adenocarcinoma.

Prendergast NJ, Walther PJ.

Surg Oncol Clin N Am. 1995 Apr;4(2):241-55. Review.

PMID:
7796284
35.

Prostate cancer screening. Why the controversy?

Walther PJ.

Surg Oncol Clin N Am. 1995 Apr;4(2):315-34. Review.

PMID:
7540938
39.
40.

Adenocarcinoma of the prostate. Part II: Tissue prognosticators.

Humphrey PA, Walther PJ.

Am J Clin Pathol. 1993 Sep;100(3):256-69. Review.

PMID:
8379534
41.

Tenascin expression in prostatic hyperplasia, intraepithelial neoplasia, and carcinoma.

Ibrahim SN, Lightner VA, Ventimiglia JB, Ibrahim GK, Walther PJ, Bigner DD, Humphrey PA.

Hum Pathol. 1993 Sep;24(9):982-9.

PMID:
7504654
42.

p53 gene alterations in human prostate carcinoma.

Effert PJ, McCoy RH, Walther PJ, Liu ET.

J Urol. 1993 Jul;150(1):257-61.

PMID:
8510267
43.

Adenocarcinoma of the prostate. I. Tissue sampling considerations.

Humphrey PA, Walther PJ.

Am J Clin Pathol. 1993 Jun;99(6):746-59. Review. No abstract available.

PMID:
8322712
44.

Treatment of high-stage bladder cancer: case for adjunctive chemotherapy.

Walther PJ.

Semin Urol. 1993 May;11(2):69-73. Review. No abstract available.

PMID:
8362122
45.

Re: Detection of human papillomavirus in squamous neoplasm of the penis.

Wiener JS, Walther PJ.

J Urol. 1993 Apr;149(4):869. No abstract available.

PMID:
8384274
46.

Squamous cell carcinoma of the prostate: 2 cases of a rare malignancy and review of the literature.

Little NA, Wiener JS, Walther PJ, Paulson DF, Anderson EE.

J Urol. 1993 Jan;149(1):137-9. Review.

PMID:
8417197
47.

Workshop summary: approaches to radical prostatectomy.

Studer UE, Walther PJ, Porter AT, Benson RC.

Eur Urol. 1993;24 Suppl 2:44-5.

PMID:
8262124
49.

Combined treatment approaches in regionally advanced bladder cancer.

Walther PJ.

Urol Clin North Am. 1992 Nov;19(4):761-74. Review.

PMID:
1441030
50.

Supplemental Content

Loading ...
Support Center